108 studies found for:    Open Studies | "Nephritis"
Show Display Options
Rank Status Study
21 Recruiting Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)
Condition: Lupus Nephritis
Intervention: Procedure: Renal Biopsy
22 Recruiting Immune System Related Kidney Disease
Conditions: Glomerulonephritis;   Lupus Nephritis;   Membranous Glomerulonephritis;   Autoimmune Disease;   Nephrotic Syndrome
Intervention:
23 Recruiting The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
Condition: Lupus Nephritis
Intervention: Drug: mycophenolic acid
24 Recruiting Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Conditions: Kidney Diseases;   Kidney Failure, Chronic;   Diabetic Nephropathy;   Lupus Nephritis;   Glomerulonephritis, IGA
Intervention:
25 Recruiting Phase Ib Study of SC Milatuzumab in SLE
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic;   Lupus Vasculitis, Central Nervous System;   Lupus Nephritis
Intervention: Drug: milatuzumab
26 Unknown  The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: calcitriol;   Drug: placebo
27 Unknown  Cyclophosphamide in Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Intervention:
28 Recruiting Prediction of Outcome of Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Intervention: Other: Serum collection
29 Recruiting ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
Condition: SLE Glomerulonephritis Syndrome, WHO Class V
Intervention: Drug: Acthar gel
30 Not yet recruiting CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Blisibimod;   Drug: Placebo
31 Recruiting Alport Syndrome Treatments and Outcomes Registry
Condition: Alport Syndrome
Intervention:
32 Recruiting ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Condition: Alport Syndrome Patients With Measured GFR Between 30-75 ml/Min
Intervention:
33 Recruiting European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Conditions: Alport Syndrome;   Hereditary Kidney Disease;   Pediatric Kidney Disease;   Thin Basement Membrane Disease;   Familial Benign Hematuria
Interventions: Drug: ACE-inhibitor;   Drug: AT1-inhibitor;   Drug: HMG-Coenzyme inhibitor (statin);   Drug: Spironolactone;   Drug: Paricalcitol
34 Recruiting Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Condition: IGA Nephropathy
Interventions: Drug: Fostamatinib 150 mg;   Drug: Fostamatinib 100 mg;   Drug: Placebo
35 Recruiting Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy
Condition: Hypertension Secondary to Renal Disease
Intervention: Procedure: Renal nerve denervation
36 Recruiting Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
Conditions: Renal Insufficiency;   Infection
Interventions: Drug: Low-dose intravenous cyclophosphamide;   Drug: High-dose intravenous cyclophosphamide
37 Recruiting Efficacy, Safety, Tolerability of Carbavance Compared to Piperacillin/Tazobactam in cUTIs, Including AP, in Adults
Conditions: Urinary Tract Infection Complicated;   Acute Pyelonephritis
Interventions: Drug: Carbavance;   Drug: Piperacillin/tazobactam;   Drug: Levofloxacin oral
38 Recruiting Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children
Condition: Acute Pyelonephritis(APN)
Intervention: Drug: Omega-3
39 Recruiting Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
Conditions: Urinary Tract Infections;   Pyelonephritis
Interventions: Drug: MK-7655 250 mg;   Drug: MK-7655 125 mg;   Drug: imipenem/cilastatin 500 mg;   Drug: Placebo to MK-7655;   Drug: Ciprofloxacin
40 Recruiting Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection
Condition: Acute Pyelonephritis
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years